Here is a brief preview of this blast: Today, a new record appeared on FDA’s 510(k) website that shows Companion Medical received clearance for additional bolus dose calculation modes in their connected app for InPen. Below, FENIX provides highlights and insights from the approval.
About The Author
Matthew Maryniak
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.